Retinoblastoma is the most common childhood tumor of the eye. It arises from undifferentiated photoreceptors (1, 2) that acquire defects in both alleles of the retinoblastoma susceptibility gene (RB1). This etiology is known as the two-hit hypothesis and was originally proposed by Knudson (3) . RB1−/− cells in the developing eye continue to divide and fill the vitreous chamber. These cells appear to have two distinct fates. Some cells attempt to complete their normal program of differentiation into cone photoreceptors (1, 2) . The majority of cells, however, undergo cell death. Most of these cells die by apoptosis, although secondary necrosis is evident in areas of widespread cell death (4) . If left untreated, retinoblastoma cells can acquire a metastatic phenotype, invading the surrounding ocular tissues, such as the choroid and optic nerve. Metastatic cells show no signs of cell death (4) , and prognosis is generally poor for patients with signs of cellular invasion, largely due to the formation of secondary metastatic tumors (5) . The aggressive nature of these cells and the lack of evidence that they exhibit any sort of cell death suggest that they have become immortalized. Consistent with this idea, several immortalized cell lines from human retinoblastomas have been generated.
Although the primary genetic defect in retinoblastoma cells is the dysfunction of RB1, expression of the tumor-suppressor gene p53 (also known as TP53) appears to play a critical role in determining the fate of RB1-/-cells. Nork et al. (4) recently showed that retinoblastoma cells have a threshold of p53 activity. Viable cells express a low level of p53, which is associated with a high level of p21/WAF1 expression. Cells about to undergo apoptosis, however, exhibit a much higher accumulation of p53. Both of these observations are consistent with the expression of normally functioning p53 in these cells. In contrast, immortalized retinoblastoma cultured cells die after transfection with an exogenous isoform of p53. This latter observation suggests that immortalized retinoblastoma cells have a dysfunctional p53 phenotype.
The idea that immortalization of retinoblastoma requires the dysfunction of both the RB1 and p53 genes is supported by several independent studies. First, the malignant phenotypes of several immortalized retinoblastoma cell lines cannot be reversed simply by the introduction of a wild-type RB1 gene (6) , suggesting that these cells also have a secondary defect. Second, the immortalization of a variety of cell types, including immature photoreceptor cells in transgenic mouse models of retinoblastoma, requires the loss of both RB1 and p53 function (7) (8) (9) . Third, Kato et al. (10) reported that cells in the primary retinoblastomas from 25 patients contained only wild-type p53 genes, but p53 was found to be mutated (cysteine 135 to phenylalanine) in a secondary metastatic retinoblastoma from one of these patients. Taken together, these studies suggest that p53 dysfunction may lead to the immortalization, and perhaps to the metastasis, of cells in retinoblastomas. Surprisingly, there has been no detailed characterization of the p53 in immortalized retinoblastoma. In this study, we characterized p53 in six independent immortalized retinoblastoma cell lines. These cells accumulate high levels of wild-type p53 but exhibit a dysfunctional p53 phenotype due to the nuclear exclusion of this transcription factor.
Methods

Cell Lines and Culture
Six independent retinoblastoma cell lines were used for this study. The strategy in using multiple cell lines was to minimize the chance of detecting an abnormality in p53 due to an artifact of cell culture. Two lines (Y79 and WERI-Rb1) were obtained from the American Type Culture Collection (ATCC) (Rockville, MD). Four lines (Rb247, Rb383, Rb412, and Rb414) were provided by Dr. Brenda Gallie of the Toronto Hospital for Sick Children in Toronto, Ontario, Canada. A small-cell lung carcinoma cell line (H510A) was also used for these experiments; this cell line was obtained from the ATCC and served as a control line that overexpressed a mutant form of p53 that accumulated in the nucleus (11) .
Y79 and WERI-Rb1 cells were cultured in RPMI-1640 medium (BioWhittaker, Inc., Walkersville, MD) containing 15% fetal bovine serum, 20 mM L-glutamine, 1000 U/mL penicillin G, 0.25 g/mL amphotericin B, and 1000 g/L streptomycin. Rb247, Rb383, Rb412, Rb414, and Y79R cells were cultured in Iscove's modified Eagle's medium (BioWhittaker, Inc.) containing 15% fetal bovine serum, 20 mM L-glutamine, 1000 U/mL penicillin G, 0.25 g/mL amphotericin B, 1000 g/mL streptomycin, 10 g/mL insulin, and 55 M 2-mercaptoethanol. H510A cells were cultured in F12K medium (BioWhittaker, Inc.) containing 15% fetal bovine serum and no antibiotic.
Western Blotting
For western blot analysis of whole cell lysates, approximately 1 × 10 7 to 1 × 10 8 cells from each line were harvested, washed twice in sterile phosphatebuffered saline (PBS), pelleted by centrifugation, and lysed in sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis sample buffer (80 mM Tris [pH 6.8], 5% 2-mercaptoethanol, 2% SDS, 20% glycerol, and 1 mM phenylmethylsulfonyl fluoride) without tracer dye. The lysates were then sonicated, and the protein concentration of each one was determined by use of a quantitative Coomassie Blue dot blot assay in which known volumes of sample were dotted onto a filter along with known amounts of bovine serum albumin (BSA). These dotted samples were then stained with Coomassie Blue, and the protein concentrations of the unknown samples were estimated by comparison with the staining of the BSA standard. Equal loading of gels used for western blotting was also confirmed by Coomassie Blue staining of duplicate gels and by western blot analysis of ␤-actin levels in each sample. Western blotting was carried out as described previously (12) , using two monoclonal antibodies that recognize both wild-type and mutant human p53 (DO-1 and p1801 at a concentration of 1 mg/L; Oncogene Science, Inc., Manhasset, NY) or a monoclonal antibody against ␤-actin (clone AC-15 at a concentration of 0.1 g/mL; Sigma Chemical Co., St. Louis, MO).
Cleavase Fragment-Length Polymorphism (CFLP) Analysis
Approximately 1 × 10 7 to 1 × 10 8 cells from each line were harvested, washed twice in sterile PBS, pelleted by centrifugation, and flash frozen. RNA was then isolated from the pelleted cells as described previously (13) . Five micrograms of total RNA was used from each line to make first-strand complementary DNA (cDNA) by use of oligo(dT) as a primer and reverse transcriptase. Basically, the RNA and 500 ng of primer were incubated together at 70°C for 2 minutes, followed by rapid cooling on ice. This mixture was then incubated with 500 M standard deoxynucleoside triphosphates (dNTPs) in a buffer containing 50 mM Tris (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , and 10 mM dithiothreitol for 10 minutes at 22°C. The synthesis of cDNA was initiated by adding 200 U of Moloney murine leukemia virus reverse transcriptase and incubating the mixture at 37°C for 60 minutes. Reactions were terminated by heating the mixtures at 90°C for 5 minutes, followed by rapidly chilling them on ice. The cDNA was then used to generate fragments for subsequent CFLP analysis.
For CFLP, the p53 coding region was split into four overlapping fragments that ranged in size from 276 base pairs (bp) to 449 bp. The primer pairs employed were based on the sequence of human wild-type p53 (GenBank Accession X02469; M60950) (14) and are as follows: for fragment A1 (294 bp, spanning codons 1 through 95), forward primer 5ЈGTCACTGCCATGGAGGAG3Ј and reverse primer 5ЈAAGATGACAGGGGCCAG-GAG3Ј; for fragment A2 (294 bp, spanning codons 75 through 173), forward primer 5ЈCACAACCTC-CGTCATGTGCTG3Ј and reverse primer 5ЈTG-CACCAGCAGCTCCTACAC3Ј; for fragment B (449 bp, spanning codons 159 through 308), forward primer 5ЈCCATGGCCATCTACAAGCAG3Ј and reverse primer 5ЈGCAGTGCTCGCTTAGT-GCTC3Ј; and for fragment C (276 bp, spanning codons 283 through stop), forward primer 5ЈTCAGTCTGAGTCAGGCCC3Ј and reverse primer 5ЈGCGCACAGAGGAAGAGAATC3Ј. Fragments A1 and A2 span exons 2 through 4 and include part of exon 5. Fragment B spans exons 5 through 9 and encompasses the six most commonly mutated sites of p53 found in human tumors (15) . Fragment C spans exons 9 through 11 and encompasses the tetramerization domain of p53, which also includes the three nuclear localization domains described by Shaulsky et al. (16) . For a wild-type control, corresponding fragments of cDNA were amplified from the plasmid pC53-SN3 (obtained from M. E. Perry at the University of Wisconsin, Madison), which contains the complete cDNA for human wild-type p53. For one mutant control, we made cDNA fragments from the p53 expressed in H510A cells; this p53 contains a point mutation in codon 282 (CGG to GGG), which is located in the B fragment. In addition, we used a synthetic point mutation in codon 358 (GAG to GGG) in the C fragment; this mutation was generated in the laboratory.
Each fragment was amplified by use of the polymerase chain reaction (PCR) from first-strand cDNA under the following conditions. Approximately 5 ng of the first-strand cDNA from each cell line was incubated in a 20-L reaction with 100 nM of each primer, 65 M dNTPs, and 0.5 U of AmpliTaq DNA Polymerase (Roche Molecular Systems, Branchburg, NJ) in a buffer containing 10 mM Tris (pH 8.3 at 25°C), 50 mM KCl, and 0.001% gelatin. The A1 and A2 fragments were originally amplified as a single 527 bp ''A'' fragment, using the forward primer for A1 and the reverse primer for A2 (see above). The conditions for this initial amplification were three cycles at 95°C for 45 seconds, 50°C for 2 minutes, and 72°C for 2 minutes, followed by 35 cycles at 95°C for 45 seconds, 55°C for 1 minute, and 72°C for 2 minutes. The B and C fragments were amplified for 30 cycles at 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute. All PCR reactions were carried out in a Perkin-Elmer 9600 Thermocycler (Roche Molecular Systems). The amplification products were purified by means of agarose gel electrophoresis and used as templates in asymmetric PCR reactions. For asymmetric PCR, each fragment was amplified with either a forward or a reverse primer that had been end-labeled [ 32 PO 4 ] . The labeled primer was used in at least 10-fold molar excess in combination with the corresponding unlabeled primer, and the amplification conditions were the same as indicated for the B and C fragments. The A1 and A2 fragments were amplified from the larger, gel-purified ''A'' fragment. Labeled fragments generated by this amplification were then separated in 6 M urea-5% polyacrylamide gels and purified by cutting out the bands that corresponded to the full-length PCR products and eluting them overnight in 500 mM ammonium acetate, 1 mM EDTA, and 0.2% SDS. Eluted DNA was organically extracted and precipitated, and the DNA precipitates were dissolved in 20 L H 2 O. Individual samples of the DNAs were then counted, and equal counts per minute of each (equivalent to 1-2 pmol of labeled DNA) were used in the comparative CFLP reactions. All reactions were conducted according to the following protocol. DNA in 5 L of H 2 O was heated at 95°C for 30 seconds and then rapidly cooled to 70°C in a Perkin-Elmer 9600 Thermocycler. Each sample was then mixed with 5 L of Cleavase digestion buffer containing 12.5 ng Cleavase enzyme (Third Wave Technologies, Inc.) (to yield a final concentration of 10 mM 3-[N-morpholino]propanesulfonic acid [pH 7.5], 0.05% Tween 20, 0.05% Nonidet P-40, and 200 M MnCl 2 ) and incubated for either 2 or 4 minutes. Reactions were stopped by the addition of 8 L of 95% formamide-10 mM EDTA gel-loading buffer. The CFLP fragments were analyzed by separating the reaction products in 6 M urea-5% polyacrylamide gels, which were then fixed, dried, and exposed to Fuji x-ray film (Fuji Photo Film Co., Tokyo, Japan) at −80°C in the presence of intensifying screens.
Localization of p53 in Cell Lines
Indirect immunofluorescence was used to localize p53 and other antigens in all cell lines. Aliquots of cells were washed in ice-cold PBS and then fixed in PBS containing 4% paraformaldehyde for 1 hour at 22°C. Fixed cells were then washed in PBS alone and ''blocked'' in PBS containing 2% BSA for 4 hours at 22°C. After blocking, the suspensions of cells were incubated with primary antibodies in PBS containing 2% BSA overnight at 4°C. The primary antibodies used in this study were the DO-1 and p1801 monoclonals directed against p53 (diluted to 5 g/mL), a polyclonal antibody directed against human Bcl-x (used at a concentration of 2 g/mL; recognizes both the long and the short forms of Bclx; Santa Cruz Biotechnology, Inc., CA), and monoclonal antibody MIB-1 directed against the human Ki-67 antigen (used at a concentration of 2.5 g/ mL; Immunotech, Inc., Westbrook, ME). After incubation with the primary antibodies, the cells were washed in PBS, spread on glass slides, and affixed by drying. Adherent cells were then incubated with an appropriate secondary antibody conjugated to Texas Red fluorescent dye (Jackson Immunoresearch Laboratories, Inc., West Grove, PA) for 4 hours at 4°C. After washing and mounting, the cells were viewed and photographed using a Zeiss Axiophot fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY).
Archived Retinoblastoma Tumor Specimens and p53 Immunocytochemistry
Procurement of eyes with histologically confirmed retinoblastoma and the subsequent immunostaining of paraffin-embedded sections of the specimens for p53 was originally described in Nork et al. (4) . The use of human residual tissue for this study was reviewed and approved by the University of Wisconsin Human Subjects Committee. The archived retinoblastoma specimens were evaluated microscopically for the localization of p53 immunoreactivity in cells of the intraocular tumors (including tumor cells that were internal to Bruch's membrane) and cells in areas of choroidal, optic nerve, or ciliary body invasion (13 of 27 specimens had regions of cellular invasion). Localization was scored as cytoplasmic or nuclear in cells with clearly defined nuclei and plasma membranes.
Results
Mutation Screening of p53 in Cell Lines
Preliminary quantitative analysis of messenger RNA in the immortalized retinoblastoma cell lines indicated that they all expressed p53 transcripts (data not shown). To examine whether the cells expressed mutant p53 transcripts, we used CFLP to screen p53 cDNAs from each cell line for mutations. In CFLP, limited digestion of DNA under defined annealing conditions yields a distinct series of fragments that are revealed by denaturing gel electrophoresis. Point mutations affect the digestion of DNAs and are detected as a change in the pattern of fragments seen on the gels (17) .
The coding sequence of p53 was divided into four regions suitable for CFLP analysis. The banding patterns for each fragment are shown in Fig. 1 . In each case, only the fragment labeled on the forward primer is shown, although the CFLP pattern was determined for each fragment in both the forward and the reverse directions. No differences were detected between the banding pattern for wild-type p53 and the banding pattern for each of the retinoblastoma cell lines. In contrast, both the mutated p53 expressed in H510A cells (mutant in fragment B) and the synthetic mutant p53 cDNA (mutant in fragment C) were detected by this method. The lack of banding differences between wild-type p53 and the cDNAs from the retinoblastoma lines suggests that either these cells express wild-type p53 mRNA or that this method does not detect all possible mutations. To investigate these possibilities, we directly sequenced p53 cDNAs isolated from Y79 cells and confirmed them to be wild-type (data not shown).
Characterization of p53 Protein in Cell Lines and Archived Tumors
Western blot analysis was conducted to determine whether the immortalized retinoblastoma cell lines accumulated significant levels of p53 protein. Fig. 2, A, shows the results of a western blot of total cell lysates probed with the DO-1 monoclonal antibody directed against p53. For comparison, an equal amount of lysate from H510A cells was included, both as a positive control for p53 and as an indicator of the relative level of expression in retinoblastoma cells. H510A cells reportedly overexpress p53 protein (11) . All of the retinoblastoma cell lines proved to have levels of p53 nearly equivalent to the level found in H510A cells. In a western blot of a duplicate gel, each sample contained uniform amounts of ␤-actin, indicating relatively equivalent protein loading. In other experiments, cell lysates were also probed with a series of antibodies that specifically recognize mutant forms of p53 (these antibodies were monoclonals Pab240 and a collection of antibodies in the mutant p53 ELISA kit available from Oncogene Research Products, Cambridge, MA). None of these mutant-specific antibodies reacted positively with any of the lysates (data not shown).
The subcellular localization of the p53 protein in the retinoblastoma and H510A cell lines was then determined by means of indirect immunofluorescence, using the p1801 monoclonal antibody directed against human p53. The distribution of p53 was compared with that of known cytoplasmic (Bcl-x) and nuclear (Ki-67) antigens (Fig. 2, B) . The distribution of p53 was cytoplasmic in Y79 cells (panel a), but it was nuclear in H510A cells (panel b), as expected based on previous reports (11) . A similar cytoplasmic distribution was detected in Y79 cells for Bcl-x (panel c). In contrast, the MIB-1 antibody, directed against the Ki-67 antigen, stained the nuclei of Y79 cells (panel d). This latter result indicated that the nuclei of Y79 cells were accessible to antibodies and that these cells exhibited normal trafficking of some polypeptides to the nucleus.
The localization of p53 in all of the retinoblastoma cell lines is shown in Fig.  3, A-F . In total, four lines exhibited marked cytoplasmic staining for p53 (Y79, WERI-Rb1, Rb412, and Rb414), while two lines (Rb247 and Rb383) appeared to have mixed nuclear and cytoplasmic staining. Part of the difficulty in examining these latter lines is that the cells had unusual morphologic characteristics, often resembling popcorn with highly lobular nuclei. In contrast, the cells from the other lines were round with spherical nuclei.
We also examined the distribution of p53 in archived retinoblastoma tumor specimens to determine the prevalence of cells with cytoplasmic p53 (Table 1 ). In 24 (89%) of 27 tumors examined, cells forming the intraocular mass exhibited nuclear staining for p53. This staining was often heterogeneous, and the cells exhibiting the strongest staining were associated with regions of high apoptotic activity, consistent with our earlier observations (4). Thirteen (48%) of these 27 specimens exhibited regions of cellular invasion into the surrounding tissues, including the optic nerve, the choroid, and the ciliary body. The p53 staining in these cells was also predominantly nuclear. Three tumors, however, showed evidence of cytoplasmic p53. In each of these specimens, only the invading cells exhibited cytoplasmic p53, whereas the majority of cells within the center of the intraocular mass exhibited nuclear staining (e.g., Fig. 3 , G and H). Exceptions were regions near the sites of initial choroidal invasion (where Bruch's membrane was compromised), which had a mixture of cells with either cytoplasmic or nuclear staining.
Discussion
Immortalized retinoblastoma cells die when transfected with an exogenous p53 construct, suggesting that they have a dysfunctional p53 phenotype (4). To explore this possibility further, we characterized the endogenous p53 gene expression in six independent retinoblastoma cell lines and compared it with the p53 expression in an immortalized cell line from a human small-cell lung carcinoma (H510A cells). Unlike the H510A cell line, which accumulates mutant p53 in the nucleus (11) , the majority of the retinoblastoma cell lines (four of six) exhibited predominantly cytoplasmic localization of wildtype p53. Two other retinoblastoma cell lines appeared to have a mixed distribution of wild-type p53 in both the nucleus and the cytoplasm.
The cytoplasmic distribution of p53 in the majority of the retinoblastoma cell lines suggests that such localization may be a mechanism of p53 dysfunction in these cells. Any event that disrupts the function of p53 as a transcription factor may lead to cellular abnormalities, particularly in cells that are already RB1-/- (18, 19) . The most common mutations in p53 resulting in oncogenic properties occur in the DNA binding domain and affect its ability to bind to DNA (20) . Nuclear exclusion of p53 can be considered to have a similar effect on the activity of this protein (21, 22) . It is noteworthy that several neuroblastoma cell lines also exhibit cytoplasmic localization of wild-type p53 (23, 24) . Ionizing radiation of immortalized neuroblastoma cells is able to shift the compartmentalization of p53 to the nucleus, thereby leading to a large increase in the number of cells undergoing G 1 arrest (24), which indicates that the endogenous p53 is functional. How ionizing radiation is able to cause a shift in the distribution of p53 is unclear, although the dramatic increase in p53 protein level following this treatment (24) may overwhelm the mechanism preventing its translocation to the nucleus. In principal, such a possibility would likely explain how exogenous p53 is able to activate apoptosis in transfected retinoblas- A synthetic cDNA containing a mutation in codon 358 (mutant) was included to serve as a positive control for the presence of a mutation. This mutation causes a new band to be formed by CFLP digestion (arrow). A close-up, with results for both wt and Y79 cells, is shown in (F). Although CFLP was able to detect both control mutations, no differences in banding pattern were detected between wild-type p53 sequences and the p53 sequences in all of the retinoblastoma cell lines. See ''Methods'' section for more details. toma cell lines (4)-this exogenous protein is expressed at high enough levels to allow a sufficient amount of it to enter the nucleus. These experiments also indicate that the p53 transduction pathway, leading to cell death, is still intact in immortalized retinoblastoma cells.
The incidence of cytoplasmic p53 in 27 human retinoblastoma tumors was also determined. Most specimens exhibited nuclear p53 staining. Three cases of cytoplasmic staining were identified, and each of these was associated with areas of cellular invasion. It is possible that these invading cells became immortalized by a defect in p53 function through nuclear exclusion, and it is intriguing to speculate that immortalization is an initial step in the metastatic process of retinoblastoma. Currently there is no evidence that immortalization would lead to metastasis of these tumors or that all metastatic retinoblastoma cells are immortal. In many cases, however, invading cells exhibit pathologic signs of aggressive cancer, such as a high mitotic index and a low nuclear to cytoplasm ratio. These cells rarely show signs of cell death similar to those seen in the vitreal tumor of the same eye (4), consistent with the existence of an immortalized population.
A potential caveat to the conclusions drawn in this study is the discrepancy between the prevalence of cytoplasmic p53 in the invading cells of the tumors and in the cells of the immortalized lines. Immortalization of cells in tumors could be associated with a loss of p53 activity either by nuclear exclusion (21, 22, 25) or by mutation (15, 25) , the latter being frequently associated with high levels of nuclear accumulation (26) . Recently, Kato et al. (10) reported that metastatic retinoblastoma cells isolated from lung tissue had mutations in both the RB1 gene and the p53 gene, unlike the cells of the original eye tumor, which had just the RB1 defect. Tumor cells with cytoplasmic p53, although rare, may have a selective advantage in surviving the transition from primary cells in culture to an immortalized cell line. This latter possibility is supported by the association between cytoplasmic localization of p53 and more aggressive cancers. Patients with colorec- tal adenocarcinoma or stage II breast cancer have a reduced survival rate if their tumors are marked by cytoplasmic staining of p53 (27, 28) . Interestingly, in a genetic study of breast cancer, the majority of tumors with cytoplasmic localization were found to be expressing wild-type p53 (25) .
The mechanism of nuclear exclusion of p53 in retinoblastoma is not clear. Cotransfection of murine erythroleukemia cells with plasmids overexpressing p53, Bcl-2, and c-Myc causes the nuclear exclusion of p53 (22) . Immortalized retinoblastoma cells express a similar combination of genes. These cells produce high levels of N-Myc (29) , which is also normal for developing retinal tissue (30) . In addition, retinoblastomas with amplified N-myc genes have been described (29) .
Our observations also indicate that Bcl-x L (i.e., the long form of Bcl-x) is highly expressed in these cells (see Fig. 2 , B, and data not shown). Both N-Myc and Bcl-x L are reported to have similar functions to c-Myc and Bcl-2, respectively, suggesting that an interaction of these gene products may regulate p53 trafficking. The exact mechanism of this interaction is not known, although it may be through a secondary modification of p53.
All retinoblastoma cells have abnormalities in both alleles of the RB1 gene. This defect may be sufficient to initiate the rapid growth of developing retinal cells and may also be a primary factor in their inability to differentiate. The expression of wild-type p53 appears to be part of the body's normal defense to eliminate these cells by apoptosis. Dysfunction of p53, however, may seriously attenuate this defense mechanism. Our observations suggest that nuclear exclusion of p53, although still wild-type, is a mechanism for immortalization of RB1-/-retinoblastoma cells. These results indicate that p53 may be one possible target for a Knudson-like third hit that could lead to more aggressive behavior of this cancer.
